These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 2189913

  • 1. Beta-lactamases, beta-lactamase inhibitors, and skin and skin-structure infections.
    Neu HC.
    J Am Acad Dermatol; 1990 May; 22(5 Pt 1):896-904. PubMed ID: 2189913
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Evolution of beta-lactamase inhibitors.
    Rolinson GN.
    Surg Gynecol Obstet; 1991 May; 172 Suppl():11-6. PubMed ID: 2024221
    [Abstract] [Full Text] [Related]

  • 4. Implications of beta-lactamase-inhibitor combinations.
    Fuchs PC, Barry AL.
    J Reprod Med; 1990 Mar; 35(3 Suppl):317-21. PubMed ID: 2319514
    [Abstract] [Full Text] [Related]

  • 5. Contribution of beta-lactamases to bacterial resistance and mechanisms to inhibit beta-lactamases.
    Neu HC.
    Am J Med; 1985 Nov 29; 79(5B):2-12. PubMed ID: 3907341
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Parenteral beta-lactamase inhibitor combinations for clinical use.
    Manzella JP.
    Am Fam Physician; 1995 May 15; 51(7):1695-8. PubMed ID: 7754928
    [Abstract] [Full Text] [Related]

  • 8. Stability in the presence of widespread beta-lactamases. A prerequisite for the antibacterial activity of beta-lactam drugs.
    Schito GC, Pesce A, Debbia EA.
    Drugs; 1994 May 15; 47 Suppl 3():1-8; discussion 8-9. PubMed ID: 7518761
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Three decades of beta-lactamase inhibitors.
    Drawz SM, Bonomo RA.
    Clin Microbiol Rev; 2010 Jan 15; 23(1):160-201. PubMed ID: 20065329
    [Abstract] [Full Text] [Related]

  • 12. beta-Lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone.
    Williams JD.
    Clin Infect Dis; 1997 Mar 15; 24(3):494-7. PubMed ID: 9114205
    [Abstract] [Full Text] [Related]

  • 13. [Mechanisms of resistance in Enterobacteriaceae towards beta-lactamase antibiotics].
    Susić E.
    Acta Med Croatica; 2004 Mar 15; 58(4):307-12. PubMed ID: 15700687
    [Abstract] [Full Text] [Related]

  • 14. Development of beta-lactamase inhibitors.
    Sutherland R.
    J Reprod Med; 1990 Mar 15; 35(3 Suppl):307-12. PubMed ID: 2319512
    [Abstract] [Full Text] [Related]

  • 15. β-lactam/β-lactamase inhibitor combinations: from then to now.
    Toussaint KA, Gallagher JC.
    Ann Pharmacother; 2015 Jan 15; 49(1):86-98. PubMed ID: 25361682
    [Abstract] [Full Text] [Related]

  • 16. What do beta-lactamases mean for clinical efficacy?
    Neu HC.
    Infection; 1983 Jan 15; 11 Suppl 2():S74-80. PubMed ID: 6423546
    [Abstract] [Full Text] [Related]

  • 17. Comparative evaluation of the in vitro activity of three combinations of beta-lactams with beta-lactamase inhibitors: piperacillin/tazobactam, ticarcillin/clavulanic acid and ampicillin/sulbactam.
    Sader HS, Tosin I, Sejas L, Miranda E.
    Braz J Infect Dis; 2000 Feb 15; 4(1):22-8. PubMed ID: 10788842
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.